共 22 条
- [21] SEEWALDT VL, 1994, AM J OBSTET GYNECOL, V170, P1666
- [22] Doxorubicin-induced cardiomyopathy[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (13) : 900 - 905Singal, PKIliskovic, N
Pegylated liposomal doxorubicin for platinum-resistant or refractory Mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience
被引：5
作者：
Fukuda, Takeshi
[1
]
Sumi, Toshiyuki
[1
]
Teramae, Masatomo
[1
]
Nakano, Yusuke
[1
]
Morishita, Masanari
[1
]
Terada, Hiroyuki
[1
]
Yoshida, Hiroyuki
[1
]
Matsumoto, Yoshinari
[1
]
Yasui, Tomoyo
[1
]
Ishiko, Osamu
[1
]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Obstet & Gynecol, Abeno Ku, Osaka 5458585, Japan
关键词：
pegylated liposomal doxorubicin;
Mullerian carcinoma;
ovarian carcinoma;
platinum resistance;
II CLINICAL-TRIAL;
PHASE-II;
CANCER;
CHEMOTHERAPY;
PACLITAXEL;
CYCLOPHOSPHAMIDE;
METAANALYSIS;
CISPLATIN;
D O I：
10.3892/ol.2012.971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of the present study was to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with Mullerian carcinoma treated at our hospital. Nineteen patients with platinum-resistant Mullerian carcinoma were treated with intravenous PLD 50 mg/m(2) every 4 weeks. Tumor response was assessed by MRI following every 2-3 cycles of treatment. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (v3.0). The best overall responses in the 19 patients were identified as 5 partial responses (PR), 6 stable diseases (SD) and 8 progressive diseases (PD). Response rate was 26.3%. The proportion of patients with CR, PR or SD was 57.9%. The median time to progression was 188.0 days. The median survival time was 381.0 days. Toxicity grades were identified as one grade III hand-foot syndrome, two grade III neutropenia, one grade IV hand-foot syndrome, one grade IV stomatitis and one grade IV neutropenia. The present study confirmed that PLD is an effective drug when administered as a salvage therapy for the treatment of Mullerian carcinoma and is associated with a reduced toxicity profile compared with current therapeutic options.
引用
收藏
页码：35 / 38
页数：4
相关论文